Repurposing FDA-approved drugs for SARSCoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

{{article.zuoZheEn}}

PDF(811 KB)
PDF(811 KB)
Protein Cell ›› 2021, Vol. 12 ›› Issue (7) : 586-591. DOI: 10.1007/s13238-020-00803-w
LETTER

Repurposing FDA-approved drugs for SARSCoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Keywords

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Protein Cell, 2021, 12(7): 586‒591 https://doi.org/10.1007/s13238-020-00803-w

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
PDF(811 KB)

Accesses

Citations

Detail
Sections
Recommended

/

〈 〉